Performance Study with the SiMoT System for in Vitro Diagnostic Tests

NCT ID: NCT06518967

Last Updated: 2025-02-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-07-16

Study Completion Date

2025-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Advanced and performing technologies able to analyze specific biomarkers for the diagnosis, prognosis and prediction as well as for the monitoring, the personalized care and the evaluation of the therapeutic response to pathologies, is currently considered extremely relevant. Such technologies work only if molecular markers specific for a given pathology have been already validated. This approach is considered of strategic importance for the health and well-being of citizens as well as for the sustainability of public spending. Often, however, the analysis of the markers is carried out on tissues or fluids of the organs involved, being hence quite invasive procedures. In this scenario, it is strategic to develop devices and platforms that allow the analysis of markers in a minimally invasive or non-invasive way, through the analysis of peripheral biological fluids, such as blood or urine. The goal is to provide clinicians with the attacker's advantage against a plethora of progressive diseases by mass-screening individuals who are affected by a disease long before symptoms appear or to allow the identification of those patients who have a high probability of recurring or responding to target-oriented pharmacological approaches. This study pertains to the definition of the analytical performance of the Single-Sensor Single-Molecule with a large Transistor (SiMoT) device. In the context of the present performance study, the IVD SiMoT system will be equipped with an accessory-cartridge developed and produced without any diagnostic purpose but only to verify the analytical performance of the SiMoT system, in the detection of exogenous biochemical molecules suitably selected to act as markers of interest.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Advanced and performing technologies able to analyze specific biomarkers for the diagnosis, prognosis and prediction as well as for the monitoring, the personalized care and the evaluation of the therapeutic response to pathologies, is currently considered extremely relevant. Such technologies work only if molecular markers specific for a given pathology have been already validated. This approach is considered of strategic importance for the health and well-being of citizens as well as for the sustainability of public spending. Among the pathologies that will increasingly be monitored and treated thanks to enabling technologies for precision medicine, tumors are certainly of particular importance. Often, however, the analysis of the markers is carried out on tissues or fluids of the organs involved, being hence quite invasive procedures. In this scenario, it is strategic to develop devices and platforms that allow the analysis of markers in a minimally invasive or non-invasive way, through the analysis of peripheral biological fluids, such as blood or urine. The goal is to provide clinicians with the attacker's advantage against a plethora of progressive diseases by mass-screening individuals who are affected by a disease long before symptoms appear or to allow the identification of those patients who have a high probability of recurring or responding to target-oriented pharmacological approaches.

This study pertains to the definition of the analytical performance of the Single-Sensor Single-Molecule with a large Transistor (SiMoT) device. The SiMoT device is an in vitro diagnostic - IVD system (REGULATION (EU) 2017/746, IVDR Art. 2, point 2) that performs decentralized analyses (near-patient testing, such as, for example, patient's home, emergency unit, ambulance) composed of a palm reader completed by machine-learning / artificial-intelligence software. The system works through an accessory (IVDR Art. 2, point 4) represented by a disposable cartridge, which determines the specific diagnostic application based on the molecular markers detected by the accessory. In the context of the present performance study, the IVD SiMoT system will be equipped with an accessory-cartridge developed and produced without any diagnostic purpose but only to verify the analytical performance of the SiMoT system, in the detection of exogenous biochemical molecules suitably selected to act as markers of interest.

The present performance study aims to verify the qualitative detection (on/off) of target molecules (both proteins and nucleic acids) with a single molecule threshold in 0.1 mL (10\^-20 M). The threshold is established by the limit of identification (LOI).

Analytical performance will be evaluated according to standard statistical approaches such as: analytical sensitivity, analytical specificity, trueness (bias), precision (repeatability and reproducibility), accuracy (resulting from trueness and precision), limits of detection and identification, measurement range, possible linearity, threshold values, including the determination of appropriate criteria for the collection and handling of samples and the control of known endogenous and exogenous interferences, cross reactions.

Risk evaluation (Risk-to-Benefits rationale) There are no identifiable physical, psychic and/or social risks for the patients enrolled in the study directly deriving from the procedures that will be followed for the enrollment and collection of the related data.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-interventional Analytical Performance Study on Left-over Samples

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Open

Test analysis perfomed in open to train the artificial intelligence algorithm.

analytical performance study

Intervention Type DIAGNOSTIC_TEST

analytical performance study on left-over samples with the SiMoT IVD system for in vitro diagnostic tests

Blind

Test analysis performed in blind to minimize biases when evaluating the predictive performance of the IVD under investigation.

analytical performance study

Intervention Type DIAGNOSTIC_TEST

analytical performance study on left-over samples with the SiMoT IVD system for in vitro diagnostic tests

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

analytical performance study

analytical performance study on left-over samples with the SiMoT IVD system for in vitro diagnostic tests

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Informed Consent and personal data handling consent signed by the subject;
* \> 18 years of age
* presence of neoplastic or suspected neoplastic pathology at the time of sample collection

Exclusion Criteria

* \< 18 years of age
* Participation in a clinical trial with an investigational drug or a medical device within the 30 days preceding and during the present investigation.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centro di Innovazione Regionale in Single Molecule Digital Assay

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

IRCCS Istituto Tumori Giovanni Paolo II, Gynecological Oncologic Clinic

Bari, Bari, Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SiMoT-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Point-spectroscopy Trial
NCT05183698 UNKNOWN